ClinicalTrials.gg
CompletedNCT00520780FAIR-HFUpdated Oct 14, 2021

Ferinject® Assessment in Patients With Iron Deficiency and Chronic Heart Failure (FAIR-HF)

A Phase 3 interventional study of Ferinject ® (Ferric carboxymaltose) and Normal saline (0.9%) in Chronic Heart Failure, Iron Deficiency and Iron Deficiency Anemia, sponsored by Vifor Pharma. Completed at 48 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-14.

Primary conditionAnemia, Iron-DeficiencyRegistry: Iron DeficienciesReclassifiedWhy we changed it
Registry
Iron Deficiencies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Anemia, Iron-Deficiency
Why
  1. The study's listed conditions name Anemia, Iron-Deficiency, a narrower term within Iron Deficiencies.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vifor Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.

Enrollment
9th of 57
456 · median 100
Started
2007
the only one that year
Phase 3
16 of 57
none open now
Registered
1st of 57
by date
Lead sponsor
7 of 57
Vifor Pharma

Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 9th largest by enrollment, is the only one that started in 2007, is one of 16 in phase 3, and was the 1st registered.

Anemia, Iron-Deficiency

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

This study is designed to evaluate the efficacy of Ferinject® in improving symptoms of CHF in patients with iron deficiency. Analyses will focus both on subjective and objective measures. Furthermore, the tolerability and safety of Ferinject® treatment will be evaluated.

03

Conditions studied

  • Chronic Heart Failure
  • Iron Deficiency
  • Iron Deficiency Anemia
  • Anaemia

Browse trials for

Keywords

  • Chronic Heart Failure
  • Iron deficiency
  • Iron deficiency anaemia
  • Anaemia
  • Heart disease
04

In context

Anemia, Iron-Deficiency Reclassified

601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.

This study's enrollment of 456 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.

Browse Anemia, Iron-Deficiency studies →

Lead sponsor

Vifor Pharma is the lead sponsor of 22 studies on the registry; none are open to participants now.

First submitted before Vifor Pharma became part of CSL Limited.

Compared within Anemia, Iron-Deficiency, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Iron Deficiencies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In (NYHA) II-III functional class due to stable symptomatic chronic heart failure (CHF)
  • (LVEF) 40% or lower for patients in NYHA II and 45% or lower in NYHA III
  • Screening (Hb) at least 9.5 g/dL but below or equal to 13.5 g/dL (average of 2 haemoglobin concentrations)
  • Screening ferritin below 100 µg/L, or below 300 µg/L when transferrin saturation (TSAT) is below 20%

Exclusion criteria

Exclusion Criteria:

  • History of acquired iron overload.
  • Known active infection, bleeding, active .
  • Chronic liver disease and/or screening (ALT) or aspartate transaminase (AST)
  • Anaemia due to reasons other than iron deficiency
  • therapy or renal dialysis (current or planned within the next 6 months).
  • History of erythropoietin, i.v. or oral iron therapy, and blood transfusion in previous 12 weeks and/or such therapy planned within the next 6 months.
  • Unstable angina pectoris as judged by the investigator, clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias.
  • Acute myocardial infarction or acute coronary syndrome, or stroke within the last 3 months.
  • Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac, cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery, including thoracic and cardiac surgery, within the last 3 months.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
456 participants (actual)

Study arms

  • Experimental
    1

    Drug: Ferinject ® (Ferric carboxymaltose)

  • Placebo comparator
    2

    Drug: Normal saline (0.9%)

Interventions

  • Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit. After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase).

  • DrugNormal saline (0.9%)

    During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.

07

What researchers measure

Primary outcomes

  1. Self-reported patient global assessment (PGA) and NYHA functional status 24 weeks after initiation of therapy

    Time frame: 24 weeks

Secondary outcomes

  1. Key secondary objectives (efficacy): Exercise tolerance (6-minute walk test distance). Further secondary objectives(efficacy): Health related quality of life, resource use and costs associated with the treatment, safety and tolerability

    Time frame: 24 weeks

08

Study locations

48 sites
  • Research Sites
    Buenos Aires, Argentina
  • Research Site
    Bad Nauheim, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Göttingen, Germany
  • Research Site
    Hannover, Germany
  • Research Sites
    Heidelberg, Germany
  • Research Site
    Herford, Germany
  • Research Site
    Herne, Germany
  • Research Site
    Kiel, Germany
  • Research Site
    München, Germany
  • Research Site
    Athens, Greece
  • Research Site
    Heraklion, Greece
  • Research Site
    Ascoli Piceno, Italy
  • Research Site
    Pavia, Italy
  • Research Site
    Rome, Italy
  • Research Site
    Vicenza, Italy
  • Research Site
    Stavanger, Norway
  • Research Site
    Bialystok, Poland
  • Research Site
    Krakow, Poland
  • Research Site
    Opole, Poland
  • Research Site
    Piotrkow Trybunalski, Poland
  • Research Site
    Siedlce, Poland
  • Research Site
    Torun, Poland
  • Research Site
    Walbrzych, Poland
  • Research Sites
    Warszawa, Poland
  • Research Site
    Wloclawek, Poland
  • Research Site
    Wroclaw, Poland
  • Research Site
    Zabrze, Poland
  • Research Site
    Brasov, Romania
  • Research Sites
    Bucharest, Romania
  • Reserach Site
    Craiova, Romania
  • Research Sites
    Targu Mures, Romania
  • Reserach Sites
    Moscow, Russian Federation
  • Research Sites
    Novgorod, Russian Federation
  • Resarch Sites
    St. Petersburg, Russian Federation
  • Research Site
    Alicante, Spain
  • Research Sites
    Barcelona, Spain
  • Research Site
    Bilbao, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Dnipropetrovsk, Ukraine
  • Research Site
    Donetsk, Ukraine
  • Research Site
    Kharkiv, Ukraine
  • Research Sites
    Kiev, Ukraine
  • Research Site
    Lviv, Ukraine
  • Research Site
    Mykolayiv, Ukraine
  • Research Site
    Odessa, Ukraine
  • Research Site
    Zaporozhye, Ukraine
09

References and documents

Publications

  • Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009 Dec 17;361(25):2436-48. doi: 10.1056/NEJMoa0908355. Epub 2009 Nov 17. PubMed 19920054 ↗
  • Anker SD, Colet JC, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Mori C, von Eisenhart Rothe B, Pocock S, Poole-Wilson PA, Ponikowski P; FAIR-HF committees and investigators. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Eur J Heart Fail. 2009 Nov;11(11):1084-91. doi: 10.1093/eurjhf/hfp140. PubMed 19875408 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Jul 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2007
First posted
Aug 27, 2007
Start
Apr 2007
Primary completionActual
Jul 2009
CompletionActual
Sep 2009
Last update
Oct 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00520780
Lead sponsor
Vifor Pharma
Collaborators
Syneos Health, ClinStar, LLC
Responsible party
Sponsor
First posted
Aug 27, 2007
Start date
Apr 2007
Primary completion
Jul 2009
Completion
Sep 2009
Last update
Oct 14, 2021

Study contacts

Philip A Poole-Wilson, MD FRCP
principal investigator · National Heart and Lung Institute. Faculty of Medicine. Imperial College London. Dovehouse Street, London SW3 6LY, UK

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion